YTHDC1: A Potential Drug Target for Cancer, Neurodegenerative Diseases and Autoimmune Disorders

Target Name: YTHDC1

NCBI ID: G91746

YTHDC1: A Potential Drug Target for Cancer, Neurodegenerative Diseases and Autoimmune Disorders

YTHDC1 (KIAA1966) is a protein that is expressed in most tissues of the body and is involved in various cellular processes. It is a key regulator of cell growth, differentiation, and survival. YTHDC1 has been identified as a potential drug target and a biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

Disease-related mechanisms

YTHDC1 plays a crucial role in the regulation of cell growth and differentiation. It is a negative regulator of the TGF-β pathway, which is a well-known mechanism involved in cancer development. TGF-β is a transcription factor that regulates the expression of genes involved in cell growth, differentiation, and survival. Activation of the TGF-β pathway is associated with the development of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

YTHDC1 functions as a negative regulator of the TGF-β pathway by preventing the activity of the TGF-β transcription factor. It does this by forming a complex with the TGF-β receptor, which is a protein that plays a critical role in the regulation of cell growth and differentiation. By forming this complex, YTHDC1 inhibits the activity of the TGF-β receptor, thereby preventing the transcriptional activity of the TGF-β pathway.

YTHDC1's role in cancer development

YTHDC1 has been identified as a potential drug target for cancer development. Several studies have shown that YTHDC1 is involved in the regulation of cancer cell growth and survival. For example, a study by Kim et al. (2019) found that YTHDC1 was expressed in various types of cancer cells and that its expression was associated with the poor prognosis of these diseases.

Another study by Zhang et al. (2020) found that YTHDC1 was positively correlated with the expression of the PD-L1 gene, which is a known regulator of cancer cell survival. The authors suggested that YTHDC1 may play a role in the regulation of cancer cell survival by suppressing the PD-L1 gene.

YTHDC1's role in neurodegenerative diseases

YTHDC1 has also been identified as a potential drug target for neurodegenerative diseases. Several studies have shown that YTHDC1 is involved in the regulation of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.

For example, a study by Li et al. (2019) found that YTHDC1 was expressed in the brains of individuals with Alzheimer's disease and that its expression was associated with the severity of the disease. The authors suggested that YTHDC1 may play a role in the regulation of neurodegenerative diseases by suppressing the activity of the PD-L1 gene.

YTHDC1's role in autoimmune disorders

YTHDC1 has also been identified as a potential drug target for autoimmune disorders. Several studies have shown that YTHDC1 is involved in the regulation of autoimmune disorders, including rheumatoid arthritis and multiple sclerosis.

For example, a study by Wang et al. (2019) found that YTHDC1 was expressed in the synovial tissues of individuals with rheumatoid arthritis and that its expression was associated with the severity of the disease. The authors suggested that YTHDC1 may play a role in the regulation of autoimmune disorders by suppressing the activity of the PD-L1 gene.

Potential therapeutic applications

The potential therapeutic applications of YTHDC1 are vast and continue to be explored. Several studies have shown that YTHDC1 may be a useful drug target for cancer, neurodegenerative diseases, and autoimmune disorders.

For cancer, YTHDC1 may be a useful drug target because of its involvement in the regulation of cell growth and differentiation. By inhibiting the activity of

Protein Name: YTH Domain Containing 1

Functions: Regulator of alternative splicing that specifically recognizes and binds N6-methyladenosine (m6A)-containing RNAs (PubMed:25242552, PubMed:26318451, PubMed:26876937, PubMed:28984244). M6A is a modification present at internal sites of mRNAs and some non-coding RNAs and plays a role in the efficiency of mRNA splicing, processing and stability (PubMed:25242552, PubMed:26318451). Acts as a key regulator of exon-inclusion or exon-skipping during alternative splicing via interaction with mRNA splicing factors SRSF3 and SRSF10 (PubMed:26876937). Specifically binds m6A-containing mRNAs and promotes recruitment of SRSF3 to its mRNA-binding elements adjacent to m6A sites, leading to exon-inclusion during alternative splicing (PubMed:26876937). In contrast, interaction with SRSF3 prevents interaction with SRSF10, a splicing factor that promotes exon skipping: this prevents SRSF10 from binding to its mRNA-binding sites close to m6A-containing regions, leading to inhibit exon skipping during alternative splicing (PubMed:26876937). May also regulate alternative splice site selection (PubMed:20167602). Also involved in nuclear export of m6A-containing mRNAs via interaction with SRSF3: interaction with SRSF3 facilitates m6A-containing mRNA-binding to both SRSF3 and NXF1, promoting mRNA nuclear export (PubMed:28984244). Involved in S-adenosyl-L-methionine homeostasis by regulating expression of MAT2A transcripts, probably by binding m6A-containing MAT2A mRNAs (By similarity). Also recognizes and binds m6A on other RNA molecules (PubMed:27602518). Involved in random X inactivation mediated by Xist RNA: recognizes and binds m6A-containing Xist and promotes transcription repression activity of Xist (PubMed:27602518). Also recognizes and binds m6A-containing single-stranded DNA (PubMed:32663306). Involved in germline development: required for spermatogonial development in males and oocyte growth and maturation in females, probably via its role in alternative splicing (By similarity)

More Common Targets